TIDMPRTC
PureTech Health PLC
12 November 2020
12 November 2020
PureTech Health plc
PureTech Founded Entity Sonde Health Launches Self-Serve API
that Detects Symptoms of Respiratory Disease from Changes in
Voice
PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a
clinical-stage biotherapeutics company dedicated to discovering,
developing and commercialising highly differentiated medicines for
devastating diseases, is pleased to note that its Founded Entity,
Sonde Health, today announced the launch of a new Developer Portal
that provides organisations with access to Sonde's advanced vocal
biomarker-based health check technology. As part of the launch,
Sonde has introduced a new self-serve API (application programming
interface) and documentation to allow developers to quickly,
easily, and autonomously integrate Sonde's voice-enabled
respiratory symptoms checker into their own iOS and Android mobile
applications.
The full text of the announcement from Sonde is as follows:
Sonde Health Launches Self-Serve API that Detects Symptoms of
Respiratory Disease
from Changes in Voice
New Developer Portal enables any organisation to quickly,
easily, and affordably embed vocal biomarker health detection and
monitoring in its mobile apps
BOSTON-November 12, 2020-- Today, Sonde Health has revealed a
new Developer Portal that provides any team access to build with
the company's advanced vocal biomarker-based health check
technology. As part of the launch, Sonde has introduced a new
self-serve API (application programming interface) and
documentation to allow developers to quickly, easily, and
autonomously integrate Sonde's voice-enabled respiratory symptoms
checker into their own iOS and Android mobile applications.
Built on research from over 1 million voice samples and 80,000
individuals, Sonde's health condition monitoring technology uses
advanced audio signal processing and machine learning to sense and
analyse subtle changes in the voice due to changes in a person's
physiology. With a 6-second voice sample, the platform detects with
more than 70% accuracy symptoms such as coughing, shortness of
breath, and chest tightness or pain, which are found in several
respiratory diseases. Because Sonde's health check only takes a few
seconds to administer and results are delivered in real-time over
most mobile devices, scaled daily screening of large populations
can be achieved to reduce the spread of respiratory illnesses, such
as COVID-19 or influenza.
Now, this technology is officially available on a self-serve
basis to developers and organisations of all sizes worldwide.
Through Sonde Health's Developer Portal, software engineers can
quickly access all the documentation, code snippets, and tools
needed to give their users a unique and objective way to detect
respiratory conditions, including asthma, COPD, COVID-19, and
influenza from just seconds of voice.
"At Sonde, we're building products and technologies that empower
people to proactively understand and manage their health, and we
want to share them with the world," said David Liu, CEO for Sonde
Health. "We created the Developer Portal and self-serve API to spur
innovation outside of Sonde so more people can benefit from our
voice-enabled health check capabilities. We can't wait to see what
new use cases are imagined to deliver actionable health data and
insights to people."
Sonde's API platform is HIPAA compliant and allows any
organisation to utilize Sonde vocometers to collect, measure, and
score (on a scale of 0-100) voice recordings for symptoms of
respiratory disease within their own applications. Developers can
also incorporate demographic or health-based questions (such as
age, how is your cough today, etc.) into the workflow to better
tailor the resources and recommendations their app serves
users.
For instance, the technology is being used today alongside a
CDC-informed COVID-19 symptoms questionnaire and temperature
reading within the Sonde One COVID-19 symptom monitoring app. The
Developer Portal and its self-serve capabilities increase the
potential reach, speed-to-market, and adoption of Sonde's current
and future voice-based health check APIs.
With a credit card and for as little as $0.15 per health check,
healthcare providers and remote health monitoring companies, for
example, can integrate Sonde's vocal biomarker technology into
their patient-facing apps to monitor respiratory health trends,
catch symptoms early, and connect patients with provider resources
if needed. By making all the required documentation and tools
available within the portal, Sonde eliminates unnecessary delays
and enables organisations to start testing and integrating the
technology into their own software in less than a day.
Building on Sonde's API is fast, easy, and free to get started.
Simply visit Sonde Health's Developer Portal and register with an
email address. Organisations that require higher health check
volumes, customized support, and reporting can speak with Sonde's
sales team at sales@sondehealth.com.
About Sonde Health
Leveraging over 1 million voice samples from 80,000+
individuals, Sonde Health's proprietary voice-based technology
platform detects symptoms of health conditions - like depression
and respiratory disease -- from changes in voice. Using advanced
audio signal processing and machine learning, Sonde senses and
analyses subtle vocal changes due to changes in a person's
physiology to provide early health detection and monitoring.
Sonde One, its health screening app, helps large organisations
to execute a daily population screening regimen that helps reduce
the spread of COVID-19, comply with government mandates, and return
to work safely. Sonde also has broad intellectual property coverage
worldwide and licenses its technology through its API platform.
www.sondehealth.com
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercialising highly
differentiated medicines for devastating diseases, including
intractable cancers, lymphatic and gastrointestinal diseases,
central nervous system disorders and inflammatory and immunological
diseases, among others. The Company has created a broad and deep
pipeline through the expertise of its experienced research and
development team and its extensive network of scientists,
clinicians and industry leaders. This pipeline, which is being
advanced both internally and through PureTech's Founded Entities,
is comprised of 24 products and product candidates, including two
that have received US Food and Drug Administration (FDA) clearance
and European marketing authorisation. All of the underlying
programmes and platforms that resulted in this pipeline of product
candidates were initially identified or discovered and then
advanced by the PureTech team through key validation points based
on the Company's unique insights into the biology of the brain,
immune and gut, or BIG, systems and the interface between those
systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
Gelesis' future prospects, developments, and strategies. The
forward looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, our expectations regarding the potential of Sonde's Developer
Portal and those risks and uncertainties described in the risk
factors included in the regulatory filings for PureTech Health plc.
These forward-looking statements are based on assumptions regarding
the present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media
Allison Mead Talbot Ben Atwell, Rob Winder
+1 617 651 3156 +44 (0) 20 3727 1000
amt@puretechhealth.com ben.atwell@FTIconsulting.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAZZMMMGZVGGZG
(END) Dow Jones Newswires
November 12, 2020 09:04 ET (14:04 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024